2
RMD icon

2Xideas’s ResMed RMD Stock Holding History

2Xideas’s Portfolio RMD Stock Details RMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.25M Sell
16,673
-46,091
-73% -$9.55M 1.4% 14
2026
Q1 		$14.1M Sell
62,764
-11,451
-15% -$2.85M 5.52% 5
2025
Q4 		$17.9M Sell
74,215
-9,396
-11% -$2.4M 5.01% 5
2025
Q3 		$22.9M Buy
83,611
+8,397
+11% +$2.29M 4.83% 5
2025
Q2 		$19.4M Sell
75,214
-4,108
-5% -$980K 3.34% 5
2025
Q1 		$17.8M Sell
79,322
-14,183
-15% -$3.31M 2.7% 5
2024
Q4 		$21.4M Sell
93,505
-40,752
-30% -$9.81M 2.86% 6
2024
Q3 		$32.8M Sell
134,257
-16,781
-11% -$3.75M 4.42% 5
2024
Q2 		$28.9M Sell
151,038
-64,842
-30% -$13.2M 3.61% 5
2024
Q1 		$42.8M Sell
215,880
-93,151
-30% -$17.1M 5.23% 4
2023
Q4 		$53.2M Buy
309,031
+8,294
+3% +$1.27M 5.7% 4
2023
Q3 		$44.5M Buy
300,737
+23,508
+8% +$4.25M 4.92% 4
2023
Q2 		$60.6M Sell
277,229
-542
-0.2% -$121K 5.79% 4
2023
Q1 		$60.8M Sell
277,771
-4,948
-2% -$1.07M 5.85% 4
2022
Q4 		$58.8M Sell
282,719
-16,389
-5% -$3.6M 6.23% 3
2022
Q3 		$65.3M Sell
299,108
-63,910
-18% -$14.5M 6.88% 1
2022
Q2 		$76.1M Sell
363,018
-24,167
-6% -$5.14M 6.95% 2
2022
Q1 		$93.9M Buy
387,185
+5,004
+1% +$1.21M 6.62% 2
2021
Q4 		$99.6M Sell
382,181
-17,659
-4% -$4.58M 6.01% 3
2021
Q3 		$105M Buy
399,840
+1,653
+0.4% +$452K 8.02% 1
2021
Q2 		$98.2M Buy
398,187
+81,113
+26% +$17.1M 8.78% 1
2021
Q1 		$61.5M Buy
317,074
+7,218
+2% +$1.45M 6.8% 3
2020
Q4 		$65.9M Buy
+309,856
New +$61.8M 8.21% 3

Other funds holding RMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

2Xideas's RMD Position: Q2 2026 in Review

2Xideas reduced its ResMed (RMD) stake by 73% in Q2 2026, selling an estimated $9.55M and leaving 16,673 shares worth $3.25M. The position accounts for 1.4% of the portfolio, ranked #14.

2Xideas first reported a position in RMD in Q4 2020 and has held it in 23 quarters since. The position peaked at $105M in Q3 2021. 885 funds tracked by Wall St. Rank hold RMD as of Q2 2026.

  • 2Xideas held 16,673 shares of ResMed worth $3.25M as of Q2 2026.
  • 2Xideas sold 46,091 ResMed shares in Q2 2026, an estimated $9.55M.
  • ResMed made up 1.4% of 2Xideas's portfolio in Q2 2026, its #14 holding.
  • 2Xideas first reported a position in ResMed in Q4 2020 and has held it in 23 quarters since.
  • 2Xideas's ResMed position peaked at $105M in Q3 2021.
  • 885 funds tracked by Wall St. Rank held ResMed as of Q2 2026.

Based on 2Xideas's 13F filing for Q2 2026, filed 14 Aug 2026.